OKYO Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -8.95%, SMA50 -17.45%, SMA200 -23.64%). The stock’s 14-day RSI is 40.61 (neutral), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.64% below its high and over 66.99% above its low. Average 10-day trading volume of 52.71 thousand shares is below the 3-month average of 173.31 thousand, indicating normal recent market interest.

OKYO Pharma Limited generated EPS of -$0.13 over the past year. Five-year average earnings growth is -114.91%. The latest quarter delivered EPS of -$0.01. The next quarter is forecast at -$0.05. Next year's EPS is expected at $0.00. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $5.00. The high target offers 332.1% upside. The low target suggests 208.64% downside. The mean target is $6.33. This offers 290.74% upside. OKYO Pharma Limited earnings surprise history is a mixed track record. The quarter that ended January 30, 2026, missed forecasts by -85.71%. The prior quarter beat by 45.56%. Over the last six quarters, Apple has recorded several small beats. These include 45.56% in July 18, 2025.

OKYO Pharma Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.04. This means the shares are trading above this model’s fair value.

OKYO Pharma Limited (NASDAQ:OKYO) closed at $1.62 USD, losing -$0.03 (-1.82%) from the previous close of $1.65. The stock is currently mid-range between its 52-week high and low $1.34 and $3.35. With a market capitalization of about $62.15 million, OKYO Pharma Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.05). Key stats such as the average daily volume over the past year has been around 135.48 thousand shares, volume is running light vs its 52-week average. Headquartered in London, None, OKYO Pharma Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert J. Dempsey, the company employs approximately 3 people and listed since May 17, 2022. OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.

OKYO Pharma Limited has 37.61 million shares outstanding. The public float is 25.08 million shares, elevated short interest at 0.28% of float. This equals 77.25 thousand shares. The short ratio is 0.56 days. Institutional investors hold 11.05% of the float. Insiders own 33.31%. CERRONE GABRIELE M holds 62.50 thousand shares, BRANCACCIO JOHN P has 16.67 thousand shares and JACOB GARY S has 12.50 thousand shares.

OKYO Pharma Limited trades at a P/E ratio of -13.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -17.78 indicating negative book value, which may reflect financial stress. The P/FCF stands at -20.08, also below market averages.

Our AI price prediction model suggests that OKYO Pharma Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.85%, with price expected at $1.65 by May 26, 2026, within a range of $1.59 to $1.70 3-Month Outlook: Projected rise of 11.73%, reaching $1.81 by August 10, 2026, with a range of $1.74 to $1.88. 1-Year Outlook: Projected gain of 390.12%, with price at $7.94 by May 12, 2027, within a range of $2.22 to $11.76.

OKYO Pharma Limited (NASDAQ:OKYO) shares are flat 3.86% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows OKYO Pharma Limited trading at a premium to the broader market with a P/E of -13.16. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $6.80, suggesting 319.75% upside. Our AI forecast model points to short-term strength (1.85% over two weeks), a medium-term rise (11.73% over three months), and a longer-term gain (390.12% over one year), with expected trading ranges indicating moderate volatility.